Published in Emerg Infect Dis on December 01, 2009
Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog (2010) 1.81
Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS One (2010) 1.75
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis (2011) 1.64
Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis (2011) 1.45
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses (2013) 1.37
Emerging influenza antiviral resistance threats. J Infect Dis (2011) 1.32
Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev (2012) 1.31
The first influenza pandemic of the new millennium. Influenza Other Respir Viruses (2011) 1.14
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg Infect Dis (2011) 1.12
Diagnostic testing for pandemic influenza in Singapore: a novel dual-gene quantitative real-time RT-PCR for the detection of influenza A/H1N1/2009. J Mol Diagn (2010) 1.12
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus in Northern Greece. Hippokratia (2011) 1.11
The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. Clin Vaccine Immunol (2010) 1.05
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J Antimicrob Chemother (2010) 1.03
Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis (2011) 1.03
The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol (2010) 1.02
Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan. PLoS One (2012) 1.01
I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One (2012) 0.98
Rapid emergence of oseltamivir resistance. Emerg Infect Dis (2010) 0.94
Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerg Infect Dis (2011) 0.94
Decision making with regard to antiviral intervention during an influenza pandemic. Med Decis Making (2010) 0.90
Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009. J Clin Microbiol (2011) 0.89
The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res (2011) 0.85
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. Antiviral Res (2012) 0.84
Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, Iran. Tanaffos (2011) 0.84
In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res (2011) 0.82
Rapid genotypic assay for detection of oseltamivir-resistant influenza A (H1N1) viruses. J Clin Microbiol (2010) 0.79
Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy (2012) 0.78
Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand. J Virol Methods (2011) 0.78
The Management of the 2009 pandemic Influenza A H1N1 virus infection. J Thorac Dis (2012) 0.75
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor. J Virol (2016) 0.75
E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. J Infect Dis (2015) 0.75
Susceptibility of influenza A(H1N1)/pdm2009, seasonal A(H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014. Sci Rep (2017) 0.75
Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies. Infect Drug Resist (2017) 0.75
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (2009) 17.96
Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 17.76
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep (2009) 9.94
Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 8.62
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis (2009) 4.06
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol (2007) 2.77
Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR. J Clin Microbiol (2009) 1.25
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol (2002) 1.04
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (2009) 17.96
Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet (2004) 5.32
Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS). Clin Chem (2003) 4.03
Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis (2010) 3.49
Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect (2012) 3.22
Influenza virus in human exhaled breath: an observational study. PLoS One (2008) 2.89
Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol (2010) 2.55
Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol (2006) 2.44
Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis (2005) 2.43
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2005) 2.40
Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis (2010) 2.36
Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect (2011) 2.29
Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis (2010) 2.24
Effects of school closures, 2008 winter influenza season, Hong Kong. Emerg Infect Dis (2008) 2.18
Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol (2003) 2.05
Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS One (2008) 2.04
Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis (2005) 2.03
Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol (2005) 1.73
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev (2007) 1.68
Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis (2010) 1.67
Complete genome sequence of Staphylococcus lugdunensis strain HKU09-01. J Bacteriol (2010) 1.56
Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem (2004) 1.55
Factors affecting QuickVue Influenza A + B rapid test performance in the community setting. Diagn Microbiol Infect Dis (2009) 1.52
The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis (2013) 1.50
Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proc Natl Acad Sci U S A (2010) 1.42
Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol (2004) 1.42
Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol (2011) 1.37
Rhinovirus infection in hospitalized children in Hong Kong: a prospective study. Pediatr Infect Dis J (2007) 1.35
Direct bacterial identification in positive blood cultures by use of two commercial matrix-assisted laser desorption ionization-time of flight mass spectrometry systems. J Clin Microbiol (2013) 1.33
Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis (2005) 1.29
Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J Virol (2009) 1.26
Internal transcribed spacer region sequence heterogeneity in Rhizopus microsporus: implications for molecular diagnosis in clinical microbiology laboratories. J Clin Microbiol (2009) 1.23
Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2011) 1.22
Outbreak of intestinal infection due to Rhizopus microsporus. J Clin Microbiol (2009) 1.20
Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis (2005) 1.19
D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood) (2010) 1.19
Introduction of an electronic monitoring system for monitoring compliance with Moments 1 and 4 of the WHO "My 5 Moments for Hand Hygiene" methodology. BMC Infect Dis (2011) 1.17
Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect (2009) 1.16
Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. Clin Chem (2004) 1.16
Initial viral load and the outcomes of SARS. CMAJ (2004) 1.11
Molecular characterization of a catalase-negative Staphylococcus aureus subsp. aureus Strain collected from a patient with mitral valve endocarditis and pericarditis revealed a novel nonsense mutation in the katA gene. J Clin Microbiol (2011) 1.09
Emergence of NDM-1-producing Enterobacteriaceae in China. J Antimicrob Chemother (2012) 1.08
Advantages of using matrix-assisted laser desorption ionization-time of flight mass spectrometry as a rapid diagnostic tool for identification of yeasts and mycobacteria in the clinical microbiological laboratory. J Clin Microbiol (2013) 1.08
Prevention of nosocomial transmission of norovirus by strategic infection control measures. Infect Control Hosp Epidemiol (2011) 1.08
Rapid detection of reassortment of pandemic H1N1/2009 influenza virus. Clin Chem (2010) 1.07
Clinical spectrum of exophiala infections and a novel Exophiala species, Exophiala hongkongensis. J Clin Microbiol (2012) 1.07
First report of spontaneous intrapartum Atopobium vaginae bacteremia. J Clin Microbiol (2012) 1.06
Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry for identification of clinically significant bacteria that are difficult to identify in clinical laboratories. J Clin Pathol (2013) 1.05
Lichtheimia hongkongensis sp. nov., a novel Lichtheimia spp. associated with rhinocerebral, gastrointestinal, and cutaneous mucormycosis. Diagn Microbiol Infect Dis (2010) 1.04
Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by severe acute respiratory syndrome coronavirus and human coronavirus 229E. J Virol (2005) 1.04
Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents (2009) 1.02
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol (2013) 1.02
Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother (2010) 1.01
Clinical management and infection control of SARS: lessons learned. Antiviral Res (2013) 1.01
Complete genome sequence of the veterinary pathogen Staphylococcus pseudintermedius strain HKU10-03, isolated in a case of canine pyoderma. J Bacteriol (2011) 1.01
Seasonal effects of influenza on mortality in a subtropical city. BMC Infect Dis (2009) 1.00
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer (2002) 1.00
Sequential introduction of single room isolation and hand hygiene campaign in the control of methicillin-resistant Staphylococcus aureus in intensive care unit. BMC Infect Dis (2010) 0.99
First report of brain abscess caused by a satelliting phenotypic variant of Helcococcus kunzii. J Clin Microbiol (2013) 0.98
Analytical sensitivity of seven point-of-care influenza virus detection tests and two molecular tests for detection of avian origin H7N9 and swine origin H3N2 variant influenza A viruses. J Clin Microbiol (2013) 0.97
High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol (2012) 0.97
A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cell Mol Immunol (2011) 0.97
Epstein-Barr virus-associated infectious mononucleosis in Chinese children. Pediatr Infect Dis J (2003) 0.96
From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis (2013) 0.96
Epidemiology and clinical features of Shewanella infection over an eight-year period. Scand J Infect Dis (2010) 0.95
A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. J Clin Virol (2004) 0.95
Transmission of methicillin-resistant Staphylococcus aureus in the long term care facilities in Hong Kong. BMC Infect Dis (2013) 0.95
High incidence of severe influenza among individuals over 50 years of age. Clin Vaccine Immunol (2011) 0.94
Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun (2004) 0.93
Differential selection and mutation between dsDNA and ssDNA phages shape the evolution of their genomic AT percentage. BMC Genet (2005) 0.93
The NS1 protein of influenza A virus interacts with cellular processing bodies and stress granules through RNA-associated protein 55 (RAP55) during virus infection. J Virol (2012) 0.93
Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome. Clin Diagn Lab Immunol (2004) 0.93
Haemophagocytic lymphohistiocytosis: an uncommon clinical presentation of tuberculosis. Hong Kong Med J (2012) 0.92
Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. Clin Infect Dis (2007) 0.92
Continuing evolution of H9N2 influenza viruses endemic in poultry in southern China. Influenza Other Respir Viruses (2011) 0.90
The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis (2004) 0.90
Nucleocapsid protein as early diagnostic marker for SARS. Emerg Infect Dis (2004) 0.90
Rapid genotyping of swine influenza viruses. Emerg Infect Dis (2011) 0.89
design of multiplexed detection assays for identification of avian influenza a virus subtypes pathogenic to humans by SmartCycler real-time reverse transcription-PCR. J Clin Microbiol (2008) 0.88
Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice. Clin Vaccine Immunol (2014) 0.87
SARS coronavirus detection methods. Emerg Infect Dis (2005) 0.87
Viral load distribution in SARS outbreak. Emerg Infect Dis (2005) 0.87
Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma (2003) 0.86
Epidemiology of Klebsiella oxytoca-associated diarrhea detected by Simmons citrate agar supplemented with inositol, tryptophan, and bile salts. J Clin Microbiol (2012) 0.85